Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
McCormick Place, Chicago, IL, June 3-7, 2016
The 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) brought together more than 30,000 oncology professionals from around the world. This year's meeting theme, "Collective Wisdom: the Future of Patient-Centered Care and Research," pointed to the power of combining knowledge – across disciplines, disease sites, and treatment approaches – to evolve and shape the future of patient care and research. This exciting theme explored advances in big data technology that are speeding up collective discovery and revealing new insights faster than ever before.
Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Dana-Farber researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Dana-Farber scientists presented more than 70 studies, including the latest findings on immunotherapy, gastric cancer, brain cancer, and ovarian cancer, plus new findings around pediatric issues.
Join the Twitter conversation at #ASCO16Follow us on LinkedIn
Dana-Farber medical oncologist Harold Burstein, MD, PhD (@DrHBurstein), interviews colleagues Elizabeth Buchbinder, MD, Jeffrey Meyerhardt, MD, MPH, and Toni Choueiri, MD (@DrChoueiri), about key developments and takeaways from ASCO 2016.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be cancer-free three years later than patients who underwent a single transplant, according to results of a Phase 3 clinical trial presented at the annual meeting of the American Society of Clinical Oncology. The tandem transplant technique produced even better results when followed with immunotherapy agents.
A crowd-sourcing strategy aimed at accelerating research into metastatic breast cancer has registered more than 2,000 patients from all 50 states in its first seven months, report researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard at the American Society of Clinical Oncology Annual Meeting.
Studies that Dana-Farber and Dana-Farber/Boston Children's Cancer and Blood Disorders Center researchers presented include:
Deborah Schrag, MD, MPH, PresenterAlthough the location of a colorectal cancer has a big influence on survival odds, this factor isn't routinely reported or included in patient counseling, say researchers from Dana-Farber, who contend this practice needs to change.
Rachel Freedman, MD, MPH, PresenterEven though the proportion of older patients with breast cancer participating in clinical trials after surgery has increased somewhat over the past 25 years, the proportion of older patients with metastatic breast cancer in pre-surgical trials is decreasing.
Prasanna Ananth, MD, MPH, PresenterMore than 90 percent of pediatric oncology providers favored access to medical marijuana for children and adolescents with cancer, according to a survey study to be presented at the meeting.
Katie Greenzang, MD, EdM, PresenterToday, the vast majority of children with cancer go on to become long-term survivors of the disease, but many survivors experience physical or cognitive impairments later on.
Matthew Davids, MD, PresenterVenclexta™, the recently approved drug for hard-to-treat chronic lymphocytic leukemia (CLL) patients, has significant side effects; but these are manageable and often become less severe as treatment continues, according to a new study.
Read the recent interview with ASCO’s incoming President, Dana-Farber lung cancer physician and scientist Bruce Johnson, MD, in which he discusses charting a course for ASCO, and his expectations for the Society in the coming years.
Presented during the Plenary Session, Sunday, June 5
Created in 2005, the Science of Oncology Award and Lecture is presented annually in recognition of a recipient's outstanding contributions to basic or translational research in cancer.
William G. Kaelin Jr., MD, is a professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, and a senior physician at Brigham and Women's Hospital. He has dedicated years of research to understanding how mutations in tumor-suppressor genes affect cancer development. His work on the VHL protein was instrumental for the subsequent successful development of VEGF inhibitors to treat kidney cancer.
On, June 2, the day before ASCO began, The Atlantic hosted an influential panel discussion in Chicago on “The Search for Answers: Fighting Rare Cancers.” This event examined how new strategies in the fight against rare cancer can revolutionize the treatment paradigm; how rare cancer communities are mobilizing at the grassroots level; and how the White House’s recently announced moonshot initiative will impact cancer research.
Co-headlining this important conversation was Levi Garraway, MD, PhD, Associate Professor of Medicine at Dana-Farber and Harvard Medical School, who was recently named an advisor to Vice President Joe Biden’s Cancer Moonshot Initiative.
Search by last name:
Browse directory of